Cipla has reported results for second quarter ended September 30, 2015.
The company has reported 21.22% rise in its net profit at Rs 407.38 crore for the quarter ended September 30, 2015 as compared to Rs 336.07 crore for the same quarter in the previous year. The company’s total income has increased by 23.50% to Rs 3103.43 crore for the quarter under review from Rs 2512.87 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 44.38% rise in its net profit after taxes, minority interest and share of profit/(Loss) of associates at Rs 431.24 crore for the quarter ended September 30, 2015 as compared to Rs 298.68 crore for the same quarter in the previous year. Total income of the company has increased by 24.64% at Rs 3478.33 crore for quarter under review as compared to Rs 2790.59 crore for the quarter ended September 30, 2014.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: